Biotech entity
Every one of those 1 sits in a single category, fda-approval. Do No Harm is most often covered alongside American Medical Association, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Do No Harm, all published on June 12, 2026.
Last mentioned: Jun 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, fda-approval. Do No Harm is most often covered alongside American Medical Association, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Do No Harm, all published on June 12, 2026. Each carries 8 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Do No Harm. Shared-story counts are live from our verified record — not editorial picks.
Biopharma companies face a potentially shrinking market and tougher FDA standards after Senate testimony highlighted 'very low certainty evidence' for pediatric gender treatments. With systematic reviews failing to show robust benefit, pipeline programs and commercial prospects for puberty blockers and cross-sex hormones are at risk.
Source: Themercury · Ttownmedia
Do No Harm is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
